Nearly all precancerous cells in the cervix are caused by persistent infection with certain strains of human papillomavirus, commonly known as HPV. Of the more than 200 types of HPV, 12 are classified as high-risk for causing cervical changes, and two of those, HPV 16 and HPV 18, are responsible for the majority of cases. While HPV infection is extremely common, most infections clear on their own. It’s when the virus lingers and integrates into cervical cells that precancerous changes begin.
How HPV Triggers Abnormal Cell Growth
HPV doesn’t cause precancerous changes by simply being present. The virus produces two proteins that hijack normal cell behavior. One protein disables your body’s built-in tumor suppressor, a molecule called p53 that normally stops damaged cells from multiplying. With p53 out of the way, cells lose a critical checkpoint that would ordinarily pause growth and trigger repair or self-destruction.
The second viral protein targets another protective molecule that controls when cells are allowed to divide. By releasing that brake, the virus essentially forces cervical cells to keep replicating even when they shouldn’t be. Over time, this uncontrolled division creates cells that look and behave abnormally. These are the precancerous cells your doctor identifies on a Pap smear or biopsy. High-risk HPV strains like types 16 and 18 produce versions of these proteins that are far more effective at disabling cellular safeguards than low-risk strains, which is why they carry a much greater cancer risk.
Grades of Cervical Precancer
Precancerous changes are graded based on how deeply abnormal cells extend through the cervical lining. In the mildest form (CIN 1), only the lower third of the lining shows abnormal cells. In moderate dysplasia (CIN 2), abnormal cells reach further, and in the most advanced stage (CIN 3), the full thickness of the lining contains dysplastic cells. CIN 3 is the stage closest to becoming invasive cancer, though it is still confined to the surface and highly treatable.
A hallmark sign under the microscope is something called koilocytosis: cells develop a halo-like clear zone around an enlarged, irregular nucleus. This appearance is essentially the fingerprint of an active HPV infection in cervical tissue.
Most Infections Clear on Their Own
The body’s immune system clears the vast majority of HPV infections before they ever cause noticeable cell changes. Among women with a confirmed HPV infection, only about 6% develop moderate or high-grade precancerous lesions within four years. Even when low-grade changes (CIN 1) do appear, roughly 80% resolve without treatment. In one study tracking confirmed CIN 1 cases, 82% of women saw their lesions regress within two years, and only 1.5% progressed to a high-grade lesion within three years. Transient infections that the body successfully fought off regressed completely within four years in every case studied.
This is why doctors often recommend a “watch and wait” approach for CIN 1, with repeat testing in 6 to 12 months rather than immediate treatment. The concern shifts when lesions persist or when high-grade changes are found, because those are less likely to resolve and more likely to progress.
How Long the Process Takes
The progression from initial HPV infection to detectable precancerous cells is typically slow. Most cervical cancers take 10 to 20 years to develop from a persistent infection, which is why regular screening catches the vast majority of problems at a treatable stage. Within a four-year window, about 2.5% of women with a persistent HPV infection develop high-grade lesions. That slow timeline is both reassuring and a reason to stay current with screening: there is usually a long window to detect and address changes before they become dangerous.
Risk Factors Beyond HPV
HPV is the necessary ingredient, but several other factors influence whether an infection persists and progresses to precancerous cells.
Smoking
Tobacco use is one of the strongest co-factors. Carcinogenic compounds from cigarette smoke, including a chemical called benzo[α]pyrene, have been detected in the cervical mucus of smokers. This compound directly targets the same tumor-suppressing gene (p53) that HPV works to disable, essentially doubling down on the damage. Smoking also suppresses local immune function in the cervix, making it harder for the body to clear HPV naturally. Even secondhand smoke exposure increases risk, because the same carcinogens reach cervical tissue through the bloodstream.
A Weakened Immune System
Clearing HPV depends heavily on a functioning immune response, specifically the branch of immunity that uses specialized cells to hunt down infected tissue. Women with HIV have rates of high-grade cervical abnormalities roughly five times higher than women without HIV. Organ transplant recipients taking immunosuppressive medications face a similar increase in risk. Autoimmune conditions and their treatments can also impair the immune surveillance needed to keep HPV in check.
Long-Term Oral Contraceptive Use
Using hormonal birth control pills for five or more years is associated with higher rates of cervical precancer. One study found a 60% increased risk with 5 to 9 years of use and a doubled risk after 10 or more years. The exact mechanism is not fully understood, but hormonal changes in cervical tissue may make cells more vulnerable to HPV’s effects. Importantly, the elevated risk decreases after stopping oral contraceptives.
Low Folate Levels
Folate, a B vitamin found in leafy greens, legumes, and fortified grains, appears to play a protective role. Women with low red blood cell folate levels who were also infected with HPV 16 had a fivefold increase in their risk of cervical dysplasia compared to HPV-positive women with adequate folate. Researchers believe folate helps maintain the stability of DNA during cell division, so deficiency may leave cervical cells more susceptible to the damage HPV causes.
How Vaccination Has Changed the Picture
The HPV vaccine (Gardasil 9) protects against nine HPV types, including the seven responsible for most HPV-related cancers and the two that cause most genital warts. Its impact on precancerous cervical lesions has been dramatic. CDC surveillance data from 2008 to 2022 shows that among screened women aged 20 to 24, the group most likely to have been vaccinated, rates of moderate-to-severe precancerous lesions dropped by 79%, and the most advanced precancerous lesions dropped by 80%. Among women aged 25 to 29, high-grade lesions fell by 37% over the same period.
Vaccination is most effective when given before any exposure to HPV, which is why it is routinely recommended in early adolescence. But it still provides benefit for people who haven’t been exposed to all the covered strains, even if given later.
Screening Recommendations
Current guidelines from the U.S. Preventive Services Task Force recommend cervical cancer screening starting at age 21. For women 21 to 29, a Pap smear every three years is the standard approach. Starting at age 30, the preferred method shifts to HPV testing alone every five years, though a Pap smear every three years or combined HPV and Pap testing every five years are also acceptable alternatives. Screening can generally stop at age 65 for women with a history of normal results.
These intervals are designed around the slow progression timeline of HPV-related changes. Even if abnormal cells develop, routine screening at these intervals provides a wide margin to catch them early.